Smartwatch could alert doctors to brain cancer complications before they worsen

NCT ID NCT07704034

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests whether a consumer smartwatch (Apple Watch or Samsung Galaxy Watch) can continuously monitor people with leptomeningeal metastasis, a condition where cancer spreads to the fluid and membranes around the brain and spinal cord. The watch collects data on movement and symptoms, and if it detects early signs of neurological decline, it automatically alerts the participant's doctor. The goal is to see if this early warning system can reduce hospitalizations by enabling faster medical intervention.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Apple Watch Series 6+ or Samsung Galaxy Watch 4+ with a cross-platform app for passive monitoring and active alerts
What this could lead to
If successful, this approach could provide a way to catch neurological decline early in people with leptomeningeal metastasis, potentially reducing hospital stays and improving quality of life.
What could go wrong
This is a small, early feasibility study, so the smartwatch alerts may not reliably predict decline or reduce hospitalizations. The technology might also be burdensome for participants to use consistently.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Meningeal Carcinomatosis neoplastic meningitis Neurologic Manifestations

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic, Case Comprehensive Cancer Center

    Cleveland, Ohio, 44106, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.